Pamela T Soliman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6599372/publications.pdf

Version: 2024-02-01

257450 265206 1,984 61 24 42 h-index citations g-index papers 62 62 62 2577 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Malignant diseases of the uterus. , 2022, , 691-706.e5.		O
2	Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort. American Journal of Obstetrics and Gynecology, 2021, 224, 278.e1-278.e14.	1.3	7
3	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Scientific Reports, 2021, 11, 3667.	3.3	20
4	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. Gynecologic Oncology, 2021, 160, 817-826.	1.4	51
5	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. Gynecologic Oncology, 2021, 160, 827-834.	1.4	20
6	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology, 2021, 161, 104-112.	1.4	4
7	Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. American Journal of Obstetrics and Gynecology, 2021, 225, 367.e1-367.e39.	1.3	39
8	An Integrated Approach to Selecting a Prepared Medical Decision-Maker. Journal of Pain and Symptom Management, 2021, 61, 1305-1310.	1.2	2
9	Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecologic Oncology, 2021, 162, 24-31.	1.4	20
10	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research, 2021, 27, 6354-6365.	7.0	31
11	Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 232-237.	2.5	O
12	Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 92-97.	2.5	3
13	Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. International Journal of Gynecological Cancer, 2020, 30, 352-357.	2.5	8
14	A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel) Tj ETQq0 0 1627-1632.	0 rgBT /O	verlock 10 Tf :
15	Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers, 2020, 12, 2436.	3.7	8
16	Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers, 2020, 12, 686.	3.7	20
17	Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus. International Journal of Gynecological Cancer, 2020, 30, 485-490.	2.5	7
18	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. Gynecologic Oncology, 2020, 158, 236-243.	1.4	42

#	Article	IF	CITATIONS
19	Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clinical Cancer Research, 2020, 26, 581-587.	7.0	60
20	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecologic Oncology, 2019, 155, 39-50.	1.4	16
21	Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists. International Journal of Gynecological Cancer, 2019, 29, 60-67.	2.5	43
22	Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed highâ€risk endometrial cancer: A prospective study. Cancer, 2019, 125, 3347-3353.	4.1	12
23	Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecologic Oncology, 2019, 154, 328-332.	1.4	6
24	Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecologic Oncology, 2019, 154, 22-28.	1.4	23
25	Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin. Oncologist, 2019, 24, e312-e317.	3.7	16
26	Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecologic Oncology, 2018, 149, 484-490.	1.4	20
27	Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers. Gynecologic Oncology, 2018, 148, 480-484.	1.4	60
28	The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. Journal of Gynecologic Oncology, 2018, 29, e68.	2.2	9
29	Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Frontiers in Immunology, 2018, 9, 2102.	4.8	33
30	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecologic Oncology, 2018, 151, 374-380.	1.4	1
31	Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget, 2018, 9, 32321-32330.	1.8	10
32	Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecologic Oncology, 2017, 145, 55-60.	1.4	48
33	Potential immunotherapy targets in recurrent cervical cancer. Gynecologic Oncology, 2017, 145, 462-468.	1.4	19
34	Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecologic Oncology, 2017, 145, 96-101.	1.4	143
35	Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecologic Oncology, 2017, 146, 27-33.	1.4	26
36	Should We Perform Routine Peritoneal and Staging Biopsies at the Time of Risk-reducing Bilateral Salpingo-ophrectomy?. Journal of Minimally Invasive Gynecology, 2017, 24, 691.	0.6	1

#	Article	IF	Citations
37	A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecologic Oncology, 2017, 146, 234-239.	1.4	171
38	Endometrial Cancer Associated Symptoms: A Case-Control Study. Journal of Women's Health, 2016, 25, 1187-1192.	3.3	18
39	Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecologic Oncology, 2016, 143, 466-471.	1.4	49
40	Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer. Gynecologic Oncology, 2016, 142, 283-285.	1.4	11
41	Fighting cancer together: Development and implementation of shared medical appointments to standardize and improve chemotherapy education. Gynecologic Oncology, 2016, 140, 114-119.	1.4	17
42	Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?. Journal of Minimally Invasive Gynecology, 2016, 23, 186-193.	0.6	47
43	Laparoscopic hysterectomy with morcellation for a suspected uterine fibroid resulting in dissemination of cervical adenocarcinoma: A case report. Gynecologic Oncology Reports, 2015, 12, 5-6.	0.6	1
44	Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecologic Oncology, 2015, 138, 727-730.	1.4	20
45	Novel treatment of a central type, primitive neuroectodermal tumor of the ovary with postoperative pediatric medulloblastoma chemotherapy regimen: A case report and review of the literature. Gynecologic Oncology Reports, 2015, 13, 57-59.	0.6	5
46	Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation. Gynecologic Oncology Reports, 2014, 10, 28-29.	0.6	38
47	Uterine adenosarcoma: An analysis on management, outcomes, and risk factors for recurrence. Gynecologic Oncology, 2014, 135, 455-461.	1.4	84
48	Position-related injury is uncommon in robotic gynecologic surgery. Gynecologic Oncology, 2014, 135, 534-538.	1.4	23
49	Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecologic Oncology, 2014, 135, 451-454.	1.4	37
50	A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecologic Oncology, 2014, 132, 275-279.	1.4	25
51	Conversion from robotic surgery to laparotomy: A case–control study evaluating risk factors for conversion. Gynecologic Oncology, 2014, 134, 238-242.	1.4	19
52	Overall survival after pelvic exenteration for gynecologic malignancy. Gynecologic Oncology, 2014, 134, 546-551.	1.4	84
53	A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecologic Oncology, 2014, 132, 366-371.	1.4	56
54	Pelvic exenteration: Impact of age on surgical and oncologic outcomes. Gynecologic Oncology, 2014, 132, 114-118.	1.4	27

#	Article	IF	CITATIONS
55	Successful incorporation of robotic surgery into gynecologic oncology fellowship training. Gynecologic Oncology, 2013, 131, 730-733.	1.4	13
56	Analgesic and Antiemetic Requirements After Minimally Invasive Surgery for Early Cervical Cancer: A Comparison Between Laparoscopy and Robotic Surgery. Annals of Surgical Oncology, 2013, 20, 1355-1359.	1.5	33
57	Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecologic Oncology, 2012, 125, 241-244.	1.4	11
58	Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecologic Oncology, 2011, 123, 333-336.	1.4	118
59	Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. American Journal of Obstetrics and Gynecology, 2011, 204, 167.e1-167.e5.	1.3	38
60	Lymphadenectomy during endometrial cancer staging: Practice patterns among gynecologic oncologists. Gynecologic Oncology, 2010, 119, 291-294.	1.4	126
61	Limited Public Knowledge of Obesity and Endometrial Cancer Risk. Obstetrics and Gynecology, 2008, 112, 835-842.	2.4	67